Published by Coherent Market Insights
Posted on September 27, 2021
4 min readLast updated: February 2, 2026
The Opioid Induced Constipation Treatment Market report 2021-2027 highlights growth drivers, key players, and market trends.
“The Opioid Induced Constipation Treatment Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.”
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/202
Opioid-induced constipation (OIC) is caused by prolonged use of certain opioids, particularly for pain management. OIC may also be caused by taking long-term and excessive doses of narcotics with effects similar to dehydration, constipation, or nausea. OIC is a common condition affecting individuals with long-standing or steady use of powerful prescription pain medications like OxyContin, codeine and morphine, as well as individuals who take sedatives frequently or individuals who have other conditions like diarrhea, kidney or liver disease, or Crohn’s disease.
Market Dynamics
Approval and launch of new products is expected to propel growth of the opioid-induced constipation treatment market. For instance, in September 2020, Sandoz, the generics division of Novartis AG, received a positive reimbursement decision in the UK for Rizmoic (naldemedine). The National Institute for Health and Care Excellence, U.K., issued a recommendation in favor of the option for treating opioid-induced constipation in adults, after previous laxative treatment. Moreover, high prevalence of cancer is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.
The opioid-induced constipation treatment market is witnessing launch of generic products. For instance, in January 2021, Par Pharmaceutical, Inc. launched the first authorized generic version of Amitiza, indicated for the treatment of chronic idiopathic constipation and opioid-induced constipation in adult with chronic non-cancer pain.
Decrease in opioid prescribing rates is expected to hinder growth of the opioid-induced constipation treatment market. For instance, according to the Centers for Disease Control and Prevention’s surveillance summaries published in January 2020, in the U.S. opioid prescribing rates declined in all 11 states during 2010–2016 (range: 14.9% to 33.0%).
The opioid-induced constipation treatment is witnessing several divesture activities. For instance, in February 2020, AstraZeneca agreed to sublicense its global rights to Movantik (naloxegol), a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of OIC, excluding Europe, Canada and Israel, to RedHill Biopharma.
Major players operating in the opioid-induced constipation treatment market are focused on adopting collaboration and partnership strategies to enhance their market share. For instance, in April 2019, BioDelivery Sciences, a Raleigh-based pharmaceutical company, acquired exclusive rights to commercialize an opioid-induced constipation drug in the U.S and Puerto Rico under a deal with Shinogi.
Top Key Players Include In Opioid Induced Constipation Treatment Market: Daewoong Co. Ltd., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Cosmo Pharmaceuticals, AstraZeneca plc, Abbott Laboratories, Valeant Pharmaceuticals, C.B. Fleet Company, Inc., and Bayer AG.
The Opioid Induced Constipation Treatment Market is displayed in 13 Chapters:
Chapter 1: Market Overview, Drivers, Restraints and Opportunities
Chapter 2: Market Competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Production, By Types, Revenue and Market share by Types
Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications
Chapter 7: Complete profiling and analysis of Manufacturers
Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Market Forecast
Chapter 13: Opioid Induced Constipation Treatment Research Findings and Conclusion, Appendix, methodology and data source
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/202
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
Visit Our Blog For More Such Reports: https://www.coherentmarketinsights.com/blog
The post Opioid Induced Constipation Treatment Market Report 2021-2027 : Recent Study Including Regional Analysis, Applications, Growth Factors And Key Players appeared first on Gatorledger.
The main topic is the Opioid Induced Constipation Treatment Market and its growth from 2021 to 2027.
New product launches and high cancer prevalence are key growth drivers.
Major players include Daewoong Co. Ltd., Takeda Pharmaceutical, and AstraZeneca.
Explore more articles in the Research Reports category
